Valneva SE

EANS-News: Valneva SE Announces a New EB66® Cell Line Research License Agreement with Boehringer Ingelheim

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------

Licensing Agreements

Lyon (France) (euro adhoc) - July 16, 2013 - Valneva SE (Valneva) announced
today that it has signed an EB66® cell line research license agreement with
Boehringer Ingelheim for the development of animal health vaccines. This
non-exclusive agreement also includes a commercial option for future marketed
products.

Boehringer Ingelheim, currently one of Valneva's commercial licensees, is
expanding its research programs to investigate additional viruses in EB66®
cells. 

Thomas Lingelbach, President and Chief Executive Officer and Franck Grimaud,
President and Chief Business Officer of Valneva, commented, "Boehringer
Ingelheim has been a licensee to the EB66® cell line since 2010, where their
current work with the EB66® platform has resulted in their request for
additional rights to this innovative technology for the production of animal
health vaccines.  We are pleased to continue our relationship with Boehringer
Ingelheim and look forward to future results achieved with EB66® cells in the
company's development of veterinary vaccine products."

Terms of the agreement were not disclosed. 




About Valneva SE
Valneva is a new European biotech company focused on vaccine development and
antibody discovery. It was created in 2013 through the merger between Intercell
AG and Vivalis SA. Valneva's mission is to excel in both antibody discovery, and
vaccine development and commercialization, either through in-house programs or
in collaboration with industrial partners using innovative technologies
developed by the company. Valneva generates diversified revenue from both its
marketed product, a vaccine for the prevention of Japanese encephalitis
(IXIARO®),commercial partnerships around a portfolio of product candidates
(in-house and partnered), and licensed technology platforms (EB66®cell line,
VIVA|ScreenTM and IC31®)developed by Valneva that are becoming widely adopted by
the biopharmaceutical industry worldwide. Headquarted in Lyon, France, the
company employs approximately 350 people in France, Austria, Scotland, the
United States, and Japan. The internationally experienced management team has a
proven track-record across research, development, manufacturing and
commercialization

EB66® Cell Line
Valneva's EB66® cell line is a highly efficient platform for vaccine production.
It is derived from duck embryonic stem cells and today represents the only
alternative to chicken eggs for large scale manufacturing of human and
veterinary vaccines. To date, the company has more than 30 research and
commercial agreements with the world's largest pharmaceutical companies to
license its EB66® technology . A research license generally lasts between 12 and
24 months and generates payments of less than EUR  200,000. If successful it can
lead to a commercial license with upfront payments, clinical milestones and
royalties. The first veterinary vaccine using the EB66® technology received
market approval in 2012 and a New Drug application (NDA) for human pandemic
Influenza is currently under review in Japan.

www.valneva.com

Contacts:

Valneva
Laetitia Bachelot-Fontaine
Communications@valneva.com
T +33 228 07 37 10      


NewCap
Pierre Laurent
Valneva@newcap.fr 
T +33 (0)1 44 71 94 93  


Forward-Looking Statements
This press release contains certain forward-looking statements relating to the
business of Valneva, including with respect to the progress, timing and
completion of research, development and clinical trials for product candidates,
the  ability to manufacture, market, commercialize and achieve market acceptance
for product candidates, the ability to protect intellectual property and operate
the business without infringing on the intellectual property rights of others,
estimates for future performance and estimates regarding anticipated operating
losses, future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development of Valneva are
consistent with the forward-looking statements contained in this press release,
those results or developments of Valneva may not be indicative of their in the
future. In some cases, you can identify forward-looking statements by words such
as "could," "should," "may," "expects," "anticipates," "believes," "intends,"
"estimates," "aims," "targets," or similar words. These forward-looking
statements are based largely on the current expectations of Valneva as of the
date of this press release and are subject to a number of known and unknown
risks and uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any future results,
performance or achievement expressed or implied by these forward-looking
statements. In particular, the expectations of Valneva could be affected by,
among other things, uncertainties involved in the development and manufacture of
vaccines, unexpected clinical trial results, unexpected regulatory actions or
delays, competition in general, currency fluctuations, the impact of the global
and European credit crisis, and the ability to obtain or maintain patent or
other proprietary intellectual property protection. In light of these risks and
uncertainties, there can be no assurance that the forward-looking statements
made during this presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and disclaim any
intention or obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events, or otherwise.


Further inquiry note:
Valneva SE
Laetitia Bachelot-Fontaine
Communications@valneva.com
T +33 228 07 37 10

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     Valneva SE
             Gerland Plaza Techsud, 70, rue Saint Jean de Dieu 
             F-69007 Lyon
phone:       +33 4 78 76 61 01
mail:     communications@valneva.com
WWW:      www.valneva.com
sector:      Biotechnology
ISIN:        FR0004056851
indexes:     ATX Prime
stockmarkets: regulated dealing: Euronext Paris, regulated dealing/prime
             standard: Wien 
language:   English
 



Weitere Meldungen: Valneva SE

Das könnte Sie auch interessieren: